Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;16(1):68-75.
doi: 10.1007/s11102-012-0376-x.

Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas

Affiliations

Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas

Xiaomin Liu et al. Pituitary. 2013 Mar.

Abstract

We evaluated the efficacy of Gamma knife stereotactic radiosurgery (GKSR) as an adjunctive management modality for patients with drug resistant or intolerant cavernous sinus invasive prolactinomas. Twenty-two patients with cavernous sinus invasive prolactinoma underwent GKSR between 1994 and 2009. Thirteen patients were dopamine agonist (DA) resistant. Six patients were intolerant to DA. Three patients chose GKSR as their initial treatment modality in hopes they might avoid life long suppression medication. The median tumor volume was 3.0 cm3 (range 0.3–11.6). The marginal tumor dose (median= 15 Gy, range 12–25 Gy) prescribed was based on the dose delivered to the optic apparatus. The median follow-up interval was 36 months (range, 12–185). Endocrine normalization was defined as a normal serum prolactin level off DA (cure) or on DA. Endocrine improvement was defined asa decreased but still elevated serum prolactin level. Endocrine deterioration was defined as an increased serum prolactin level. Endocrine normalization was achieved in six(27.3%) patients. Twelve (54.5%) patients had endocrine improvement. Four patients (18.2%) developed delayed increased prolactin. Imaging-defined local tumor control was achieved in 19 (86.4%) patients, 12 of whom had tumor regression. Three patients had a delayed tumor progression and required additional management. One patient developed a new pituitary axis deficiency after GKSR. Invasive prolactinomas continue to pose management challenges. GKSR is a non invasive adjunctive option that may reduce prolactin levels in patients who are resistant to or intolerant of suppression medication. In a minority of cases, patients may no longer require long term suppression therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer. 2002 Jul 15;95(2):258-66 - PubMed
    1. World Neurosurg. 2010 Jul;74(1):147-52 - PubMed
    1. Radiother Oncol. 1999 Sep;52(3):233-7 - PubMed
    1. Eur J Endocrinol. 2009 May;160(5):747-52 - PubMed
    1. Neurosurgery. 1983 Jun;12(6):640-2 - PubMed

Publication types

LinkOut - more resources